Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The ATM Ser49Cys Variant Effects ATM Function as a Regulator of Oncogene-Induced Senescence.
Atkinson C, McInerney-Leo AM, Proctor M, Lanagan C, Stevenson AJ, Dehkhoda F, Caole M, Maas E, Ainger S, Pritchard AL, Johansson PA, Leo P, Hayward NK, Sturm RA, Duncan EL, Gabrielli B. Atkinson C, et al. Among authors: lanagan c. Int J Mol Sci. 2024 Jan 29;25(3):1664. doi: 10.3390/ijms25031664. Int J Mol Sci. 2024. PMID: 38338943 Free PMC article.
Combined use of subclinical hydroxyurea and CHK1 inhibitor effectively controls melanoma and lung cancer progression, with reduced normal tissue toxicity compared to gemcitabine.
Oo ZY, Proctor M, Stevenson AJ, Nazareth D, Fernando M, Daignault SM, Lanagan C, Walpole S, Bonazzi V, Škalamera D, Snell C, Haass NK, Larsen JE, Gabrielli B. Oo ZY, et al. Among authors: lanagan c. Mol Oncol. 2019 Jul;13(7):1503-1518. doi: 10.1002/1878-0261.12497. Epub 2019 Jun 14. Mol Oncol. 2019. PMID: 31044505 Free PMC article.
Endogenous Replication Stress Marks Melanomas Sensitive to CHEK1 Inhibitors In Vivo.
Oo ZY, Stevenson AJ, Proctor M, Daignault SM, Walpole S, Lanagan C, Chen J, Škalamera D, Spoerri L, Ainger SA, Sturm RA, Haass NK, Gabrielli B. Oo ZY, et al. Among authors: lanagan c. Clin Cancer Res. 2018 Jun 15;24(12):2901-2912. doi: 10.1158/1078-0432.CCR-17-2701. Epub 2018 Mar 13. Clin Cancer Res. 2018. PMID: 29535131
High efficiency ex vivo cloning of antigen-specific human effector T cells.
Neller MA, Lai MH, Lanagan CM, O'Connor LE, Pritchard AL, Martinez NR, Schmidt CW. Neller MA, et al. Among authors: lanagan cm. PLoS One. 2014 Nov 4;9(11):e110741. doi: 10.1371/journal.pone.0110741. eCollection 2014. PLoS One. 2014. PMID: 25368986 Free PMC article.
Frequent somatic mutations in MAP3K5 and MAP3K9 in metastatic melanoma identified by exome sequencing.
Stark MS, Woods SL, Gartside MG, Bonazzi VF, Dutton-Regester K, Aoude LG, Chow D, Sereduk C, Niemi NM, Tang N, Ellis JJ, Reid J, Zismann V, Tyagi S, Muzny D, Newsham I, Wu Y, Palmer JM, Pollak T, Youngkin D, Brooks BR, Lanagan C, Schmidt CW, Kobe B, MacKeigan JP, Yin H, Brown KM, Gibbs R, Trent J, Hayward NK. Stark MS, et al. Among authors: lanagan c. Nat Genet. 2011 Dec 25;44(2):165-9. doi: 10.1038/ng.1041. Nat Genet. 2011. PMID: 22197930 Free PMC article.
Durable complete clinical responses in a phase I/II trial using an autologous melanoma cell/dendritic cell vaccine.
O'Rourke MG, Johnson M, Lanagan C, See J, Yang J, Bell JR, Slater GJ, Kerr BM, Crowe B, Purdie DM, Elliott SL, Ellem KA, Schmidt CW. O'Rourke MG, et al. Among authors: lanagan c. Cancer Immunol Immunother. 2003 Jun;52(6):387-95. doi: 10.1007/s00262-003-0375-x. Epub 2003 Apr 8. Cancer Immunol Immunother. 2003. PMID: 12682787 Free PMC article. Clinical Trial.
Dendritic cell immunotherapy for stage IV melanoma.
O'Rourke MG, Johnson MK, Lanagan CM, See JL, O'Connor LE, Slater GJ, Thomas D, Lopez JA, Martinez NR, Ellem KA, Schmidt CW. O'Rourke MG, et al. Melanoma Res. 2007 Oct;17(5):316-22. doi: 10.1097/CMR.0b013e3282c3a73b. Melanoma Res. 2007. PMID: 17885587 Clinical Trial.
15 results